Incannex Announces Initiation of Research Coverage by Alliance Global Partners
Rhea-AI Summary
Incannex (Nasdaq: IXHL) announced that Alliance Global Partners has initiated equity research coverage with a BUY rating and a US$18.00 price target, in a report dated June 8, 2026 by analyst James Molloy.
The coverage evaluates Incannex’s clinical pipeline, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and is expected by the company to broaden investor awareness. AGP has received compensation from Incannex for investment banking services.
Positive
- None.
Negative
- None.
News Market Reaction – IXHL
In the Jun 9 session, IXHL gained 7.94%, reflecting a notable positive market reaction. Argus tracked a peak move of +17.5% during that session. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Clinical trial start | Positive | +0.8% | DReAMzz dose-optimization study for IHL-42X officially commenced across 14 clinical sites. |
| May 12 | Award recognition | Positive | -13.9% | MedTech Breakthrough award for IHL-42X as best new drug development technology. |
| Apr 22 | Regulatory alignment | Positive | +4.4% | PSX-001 Phase 2 data and alignment with White House order on psychedelic treatments. |
| Mar 27 | Share repurchase | Positive | -5.0% | Reactivation of share repurchase program supported by strong cash and no debt. |
| Mar 25 | Research partnership | Positive | +15.8% | Partnership with AASM Foundation to back sleep apnea research alongside IHL-42X progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive milestones have produced mixed reactions, with some clinical and partnership updates aligning with upside moves and others seeing selling pressure despite constructive news.
Over recent months, Incannex has advanced lead programs and corporate positioning. On Mar 25, it announced an AASM Foundation partnership tied to IHL-42X and broader pipeline work, followed by a share repurchase reactivation on Mar 27. In April and May, the company highlighted strong PSX-001 Phase 2 data, a MedTech Breakthrough award, and formal commencement of the DReAMzz IHL-42X study. Today’s AGP research coverage fits into this sequence of efforts to showcase clinical progress and strategy to the market.
Key Terms
equity research coverage financial
price target financial
obstructive sleep apnoea medical
psilocybin medical
generalized anxiety disorder medical
investment banking services financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to announce that Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company.
The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex’s clinical pipeline, development strategy, market opportunities and future growth prospects.
Research Coverage Highlights
- Rating: BUY
- Price Target: US
$18.00 per share - Analyst: James Molloy, Alliance Global Partners
- Report Date: June 8, 2026
Incannex believes the initiation of coverage by AGP represents an important milestone in expanding awareness of the Company’s clinical programs and investment proposition among institutional and retail investors.
The report includes discussion of the Company’s lead obstructive sleep apnoea program, IHL-42X, currently being advanced through the DReAMzz dose optimisation study, as well as PSX-001, the Company’s synthetic psilocybin program for generalized anxiety disorder.
Joel Latham, President and Chief Executive Officer of Incannex, commented:
“We are pleased AGP has elected to initiate research coverage and appreciate the time and diligence their team has dedicated to understanding our business, clinical programs and long-term strategy.”
“As we continue advancing IHL-42X and PSX-001 through development, we believe increased research coverage can help broaden investor awareness of the significant unmet needs we are seeking to address and the substantial commercial opportunities represented by our pipeline.”
Investors may contact Alliance Global Partners (www.allianceg.com) directly to obtain a copy of the report.
Analyst Disclaimer
The information above regarding analyst coverage is solely for informational purposes and is not intended as a solicitation to make investments. Any opinions, estimates or forecasts regarding Incannex’s performance made by analysts are theirs alone and do not represent opinions, forecasts or predictions of Incannex or its management. Incannex does not by its reference above, or by distribution, imply its endorsement of or concurrence with such information, conclusions or recommendations. Alliance Global Partners has received compensation from Incannex for providing investment banking services. Incannex undertakes no obligation to update or revise any such information, conclusions or recommendations, whether as a result of new information, future events or otherwise.
About Incannex Healthcare Inc.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the development, regulatory progress and commercialization of the Company’s drug candidates, potential benefits of equity research coverage, the potential value of the Company’s drug candidates and business, and potential shareholder value. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, the potential risk that equity research coverage may not result in increased investor awareness or liquidity, risks associated with the clinical development of IHL-42X and PSX-001, and other risks described in the section entitled “Risk Factors” described in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au
